Cuellar et al. first reported the function of SETDB1-mediated ERV suppression in cancer cells in 2017 when they discovered that SETDB1 silencing in AML cells elevated the expression of IFN-β and IFN-stimulated genes. This evidence concerns the gene SETDB1 and acute myeloid leukemia.